• Je něco špatně v tomto záznamu ?

Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers

A. Katonova, R. Andel, V. Jurasova, K. Veverova, F. Angelucci, V. Matoska, J. Hort

. 2025 ; 105 (1) : 159-171. [pub] 20250320

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015907

BackgroundKLOTHO-VS heterozygosity (KL-VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction.ObjectiveWe investigated whether 1) KL-VSHET is associated with lower AD biomarker burden (Aβ42, Aβ42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.MethodsParticipants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL-VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup.ResultsOverall, the associations between KL-VSHET and higher CSF Aβ42 and Aβ42/40 ratio were non-significant (ps ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL-VSHET was positively associated with Aβ42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL-VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = -0.25, p = 0.036) and a positive association with Aβ42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).ConclusionsKL-VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015907
003      
CZ-PrNML
005      
20250731091340.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/13872877251326199 $2 doi
035    __
$a (PubMed)40112321
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Katonova, Alzbeta $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000656057200
245    10
$a Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers / $c A. Katonova, R. Andel, V. Jurasova, K. Veverova, F. Angelucci, V. Matoska, J. Hort
520    9_
$a BackgroundKLOTHO-VS heterozygosity (KL-VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction.ObjectiveWe investigated whether 1) KL-VSHET is associated with lower AD biomarker burden (Aβ42, Aβ42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.MethodsParticipants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL-VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup.ResultsOverall, the associations between KL-VSHET and higher CSF Aβ42 and Aβ42/40 ratio were non-significant (ps ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL-VSHET was positively associated with Aβ42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL-VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = -0.25, p = 0.036) and a positive association with Aβ42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).ConclusionsKL-VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
650    _2
$a lidé $7 D006801
650    12
$a Alzheimerova nemoc $x mozkomíšní mok $x genetika $7 D000544
650    _2
$a proteiny Klotho $x genetika $7 D000090265
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
650    _2
$a senioři $7 D000368
650    _2
$a amyloidní beta-protein $x mozkomíšní mok $7 D016229
650    _2
$a proteiny tau $x mozkomíšní mok $7 D016875
650    _2
$a heterozygot $7 D006579
650    _2
$a peptidové fragmenty $x mozkomíšní mok $7 D010446
650    12
$a glukuronidasa $x genetika $7 D005966
650    _2
$a lidé středního věku $7 D008875
650    _2
$a apolipoprotein E4 $x genetika $7 D053327
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kognitivní dysfunkce $x mozkomíšní mok $x genetika $7 D060825
655    _2
$a časopisecké články $7 D016428
700    1_
$a Andel, Ross $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $u Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA
700    1_
$a Jurasova, Vanesa $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Veverova, Katerina $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Angelucci, Francesco $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000259565925
700    1_
$a Matoska, Vaclav $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
773    0_
$w MED00006350 $t Journal of Alzheimer's disease $x 1875-8908 $g Roč. 105, č. 1 (2025), s. 159-171
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40112321 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091334 $b ABA008
999    __
$a ok $b bmc $g 2366623 $s 1253032
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 105 $c 1 $d 159-171 $e 20250320 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...